Terra L. Reeder

发表

Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients.

A. Tefferi, A. Pardanani, T. Kimlinger, 2004, Leukemia research.

Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease.

A. Tefferi, J. Butterfield, A. Pardanani, 2003, Leukemia research.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

D. Gilliland, D. Gilliland, A. Tefferi, 2003, Blood.

Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder

A. Tefferi, A. Pardanani, T. Kimlinger, 2003, British journal of haematology.

A phase 2 trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia.

D. Steensma, R. Mesa, S. Kaufmann, 2003, Blood.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

D. Gilliland, A. Tefferi, N. Cross, 2003, Blood.

the treatment of myelofibrosis with myeloid metaplasia A phase 2 trial of combination low-dose thalidomide and prednisone for

D. Steensma, R. Mesa, A. Tefferi, 2012 .

Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia.

A. Tefferi, A. Pardanani, Chin‐Yang Li, 2003, Leukemia research.

Imatinib for systemic mast-cell disease

E. Baxter, A. Tefferi, N. Cross, 2003, The Lancet.

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic

A. Tefferi, N. Cross, T. Witzig, 2002 .

Effects of the MEK inhibitor CI-1040 (PD 184352) on progenitor growth from normal and myelodysplastic marrow.

D. Steensma, R. Mesa, S. Kaufmann, 2003, Haematologica.

Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia.

A. Tefferi, G. Dewald, R. Bailey, 2003, Blood.

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.

E. Baxter, A. Tefferi, N. Cross, 2003, Blood.

disorders Imatinib therapy for hypereosinophilic syndrome and other eosinophilic

E. Baxter, A. Tefferi, H. Tazelaar, 2013 .

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic

A. Tefferi, H. Tazelaar, A. Pardanani, 2002 .

In vitro antiproliferative activity of the farnesyltransferase inhibitor R115777 in hematopoietic progenitors from patients with myelofibrosis with myeloid metaplasia

R. Mesa, S. Kaufmann, A. Tefferi, 2003, Leukemia.